

# Richard SchÄœfer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7913832/publications.pdf>

Version: 2024-02-01

61  
papers

3,905  
citations

126907

33  
h-index

128289

60  
g-index

64  
all docs

64  
docs citations

64  
times ranked

6397  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical use of Convalescent Plasma in the COVID-19 pandemic: a transfusion-focused gap analysis with recommendations for future research priorities. Vox Sanguinis, 2021, 116, 88-98.	1.5	30
2	Human Mesenchymal Stromal Cells Are Resistant to SARS-CoV-2 Infection under Steady-State, Inflammatory Conditions and in the Presence of SARS-CoV-2-Infected Cells. Stem Cell Reports, 2021, 16, 419-427.	4.8	34
3	Neglected No More: Emerging Cellular Therapies in Traumatic Injury. Stem Cell Reviews and Reports, 2021, 17, 1194-1214.	3.8	4
4	Implications of hematopoietic stem cells heterogeneity for gene therapies. Gene Therapy, 2021, 28, 528-541.	4.5	12
5	More Human BM-MSC With Similar Subpopulation Composition and Functional Characteristics Can Be Produced With a GMP-Compatible Fabric Filter System Compared to Density Gradient Technique. Frontiers in Cell and Developmental Biology, 2021, 9, 638798.	3.7	5
6	Depletion of CD45RA+ T cells: Advantages and disadvantages of different purification methods. Journal of Immunological Methods, 2021, 492, 112960.	1.4	1
7	Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies. Transfusion Medicine and Hemotherapy, 2021, 48, 137-147.	1.6	21
8	Modeling alcohol-induced neurotoxicity using human induced pluripotent stem cell-derived three-dimensional cerebral organoids. Translational Psychiatry, 2020, 10, 347.	4.8	47
9	Modulating endothelial adhesion and migration impacts stem cell therapies efficacy. EBioMedicine, 2020, 60, 102987.	6.1	10
10	Cell motility and migration as determinants of stem cell efficacy. EBioMedicine, 2020, 60, 102989.	6.1	26
11	Human Mesenchymal Stromal Cell (MSC) Characteristics Vary Among Laboratories When Manufactured From the Same Source Material: A Report by the Cellular Therapy Team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Frontiers in Cell and Developmental Biology, 2020, 8, 458.	3.7	28
12	Gaps in the knowledge of human platelet lysate as a cell culture supplement for cell therapy: a joint publication from the AABB and the International Society for Cell & Gene Therapy. Transfusion, 2019, 59, 3448-3460.	1.6	57
13	Gaps in the knowledge of human platelet lysate as a cell culture supplement for cell therapy: a joint publication from the AABB and the International Society for Cell & Gene Therapy. Cytotherapy, 2019, 21, 911-924.	0.7	42
14	Production and quality testing of multipotent mesenchymal stromal cell therapeutics for clinical use. Transfusion, 2019, 59, 2164-2173.	1.6	20
15	Advanced cell therapeutics are changing the clinical landscape: will mesenchymal stromal cells be a part of it?. BMC Medicine, 2019, 17, 53.	5.5	12
16	Quantitation of progenitor cell populations and growth factors after bone marrow aspirate concentration. Journal of Translational Medicine, 2019, 17, 115.	4.4	54
17	Molecular signature of human bone marrow-derived mesenchymal stromal cell subsets. Scientific Reports, 2019, 9, 1774.	3.3	35
18	Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM" Outcome Report of 92 Patients. Cells, 2019, 8, 1577.	4.1	38

#	ARTICLE	IF	CITATIONS
19	Single-Cell Transcriptomics of Human Mesenchymal Stem Cells Reveal Age-Related Cellular Subpopulation Depletion and Impaired Regenerative Function. <i>Stem Cells</i> , 2019, 37, 240-246.	3.2	46
20	Extracellular Vesicles Derived from Mesenchymal Stem/Stromal Cells: Current Approaches to Enhance Their Release and Therapeutic Potential. , 2019, , 101-111.		0
21	Manufacture of endothelial colony-forming progenitor cells from steady-state peripheral blood leukapheresis using pooled human platelet lysate. <i>Transfusion</i> , 2018, 58, 1132-1142.	1.6	36
22	Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). <i>Bone Marrow Transplantation</i> , 2018, 53, 852-862.	2.4	77
23	Human mesenchymal stromal cells undergo apoptosis and fragmentation after intravenous application in immune-competent mice. <i>Cytotherapy</i> , 2017, 19, 61-74.	0.7	36
24	High-Resolution Microfluidic Single-Cell Transcriptional Profiling Reveals Clinically Relevant Subtypes among Human Stem Cell Populations Commonly Utilized in Cell-Based Therapies. <i>Frontiers in Neurology</i> , 2016, 7, 41.	2.4	12
25	Characterization of mesenchymal stem or stromal cells: tissue sources, heterogeneity, and function. <i>Transfusion</i> , 2016, 56, 2S-5S.	1.6	4
26	Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future. <i>Stem Cell Research and Therapy</i> , 2016, 7, 93.	5.5	143
27	Mesenchymal Stem/Stromal Cells in Regenerative Medicine: Can Preconditioning Strategies Improve Therapeutic Efficacy. <i>Transfusion Medicine and Hemotherapy</i> , 2016, 43, 256-267.	1.6	105
28	Short-term preconditioning enhances the therapeutic potential of adipose-derived stromal/stem cell-conditioned medium in cisplatin-induced acute kidney injury. <i>Experimental Cell Research</i> , 2016, 342, 175-183.	2.6	41
29	Unraveling the Mesenchymal Stromal Cells' Paracrine Immunomodulatory Effects. <i>Transfusion Medicine Reviews</i> , 2016, 30, 37-43.	2.0	144
30	Where is the common ground between bone marrow mesenchymal stem/stromal cells from different donors and species?. <i>Stem Cell Research and Therapy</i> , 2015, 6, 143.	5.5	47
31	Comparison of Cardiomyocyte Differentiation Potential between Type 1 Diabetic Donor- and Nondiabetic Donor-Derived Induced Pluripotent Stem Cells. <i>Cell Transplantation</i> , 2015, 24, 2491-2504.	2.5	21
32	Biological Differences Between Native and Cultured Mesenchymal Stem Cells: Implications for Therapies. <i>Methods in Molecular Biology</i> , 2015, 1235, 105-120.	0.9	21
33	Cell-based therapies for cardiac disease: a cellular therapist's perspective. <i>Transfusion</i> , 2015, 55, 441-451.	1.6	31
34	A Simple "Blood-Saving Bundle" Reduces Diagnostic Blood Loss and the Transfusion Rate in Mechanically Ventilated Patients. <i>PLoS ONE</i> , 2015, 10, e0138879.	2.5	39
35	Intranasal Delivery of Bone Marrow-Derived Mesenchymal Stem Cells, Macrophages, and Microglia to the Brain in Mouse Models of Alzheimer's and Parkinson's Disease. <i>Cell Transplantation</i> , 2014, 23, 123-139.	2.5	114
36	Interplay between Endothelin and Erythropoietin in Astroglia: The Role in Protection against Hypoxia. <i>International Journal of Molecular Sciences</i> , 2014, 15, 2858-2875.	4.1	8

#	ARTICLE	IF	CITATIONS
37	Intraarterial transplantation of human umbilical cord blood mononuclear cells is more efficacious and safer compared with umbilical cord mesenchymal stromal cells in a rodent stroke model. <i>Stem Cell Research and Therapy</i> , 2014, 5, 45.	5.5	52
38	Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. <i>BMC Medicine</i> , 2013, 11, 146.	5.5	367
39	Mesenchymal stromal/stem cells markers in the human bone marrow. <i>Cytotherapy</i> , 2013, 15, 292-306.	0.7	93
40	Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 12774-12779.	7.1	137
41	Does the Adult Stroma Contain Stem Cells?. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2012, 129, 177-189.	1.1	3
42	Bone Marrow-Derived Human Mesenchymal Stem Cells Express Cardiomyogenic Proteins But Do Not Exhibit Functional Cardiomyogenic Differentiation Potential. <i>Stem Cells and Development</i> , 2012, 21, 2457-2470.	2.1	64
43	No red cell alloimmunization or change of clinical outcome after using fresh frozen cancellous allograft bone for acetabular reconstruction in revision hip arthroplasty: a follow up study. <i>BMC Musculoskeletal Disorders</i> , 2012, 13, 187.	1.9	0
44	Human Term Placenta-Derived Mesenchymal Stromal Cells Are Less Prone to Osteogenic Differentiation Than Bone Marrow-Derived Mesenchymal Stromal Cells. <i>Stem Cells and Development</i> , 2011, 20, 635-646.	2.1	88
45	Therapeutic Efficacy of Intranasally Delivered Mesenchymal Stem Cells in a Rat Model of Parkinson Disease. <i>Rejuvenation Research</i> , 2011, 14, 3-16.	1.8	225
46	Expression of blood group genes by mesenchymal stem cells. <i>British Journal of Haematology</i> , 2011, 153, 520-528.	2.5	31
47	Animal serum-free expansion and differentiation of human mesenchymal stromal cells. <i>Cytotherapy</i> , 2010, 12, 143-153.	0.7	56
48	Functional investigations on human mesenchymal stem cells exposed to magnetic fields and labeled with clinically approved iron nanoparticles. <i>BMC Cell Biology</i> , 2010, 11, 22.	3.0	71
49	Labeling and Imaging of Stem Cells – Promises and Concerns. <i>Transfusion Medicine and Hemotherapy</i> , 2010, 37, 1-1.	1.6	8
50	Intranasal delivery of cells to the brain. <i>European Journal of Cell Biology</i> , 2009, 88, 315-324.	3.6	299
51	Labeling of human mesenchymal stromal cells with superparamagnetic iron oxide leads to a decrease in migration capacity and colony formation ability. <i>Cytotherapy</i> , 2009, 11, 68-78.	0.7	81
52	The Immunosuppressive Properties of Mesenchymal Stem Cells. <i>Transplantation</i> , 2009, 87, S45-S49.	1.0	165
53	Lactate modulates gene expression in human mesenchymal stem cells. <i>Langenbeck's Archives of Surgery</i> , 2008, 393, 297-301.	1.9	37
54	Characteristics of Mesenchymal Stem Cells – New Stars in Regenerative Medicine or Unrecognized Old Fellows in Autologous Regeneration?. <i>Transfusion Medicine and Hemotherapy</i> , 2008, 35, 154-159.	1.6	10

#	ARTICLE	IF	CITATIONS
55	Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood, 2008, 111, 2152-2154.	1.4	167
56	The Use of Clinically Approved Small Particles of Iron Oxide (SPIO) for Labeling of Mesenchymal Stem Cells Aggravates Clinical Symptoms in Experimental Autoimmune Encephalomyelitis and Influences Their In Vivo Distribution. Cell Transplantation, 2008, 17, 923-941.	2.5	38
57	Aptamer-Based Strategies for Stem Cell Research. Mini-Reviews in Medicinal Chemistry, 2007, 7, 701-705.	2.4	23
58	Transferrin Receptor Upregulation: In Vitro Labeling of Rat Mesenchymal Stem Cells with Superparamagnetic Iron Oxide. Radiology, 2007, 244, 514-523.	7.3	97
59	Are Indoleamine-2,3-Dioxygenase Producing Human Dendritic Cells a Tool for Suppression of Allogeneic T-cell Responses?. Transplantation, 2007, 83, 468-473.	1.0	20
60	A New Technique for the Isolation and Surface Immobilization of Mesenchymal Stem Cells from Whole Bone Marrow Using High-Specific DNA Aptamers. Stem Cells, 2006, 24, 2220-2231.	3.2	148
61	Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome. Journal of Molecular Medicine, 2006, 84, 378-388.	3.9	222